Shares in several sectors set to gain as lockdown eased
Stocks of cinemas, restaurants, retailers and department stores that were laggards during the lockdown can expect growth after the curfew is relaxed, said analysts from GBS Globlex Securities and Country Group Securities (CGS).
Wilasinee Boonmasungsong, research director of GBS Globlex Securities, said shares in several sectors are set to benefit from the Centre for Covid-19 Situation Administration's decision to ease the lockdown measures by shortening curfew hours.
She said the easing of lockdown measures will extend the opening hours of restaurants and department stores and help improve sentiment in the stock market during the period.
Analysts at CGS view that stocks that will benefit the most from the easing of lockdown measures are cinemas, retailers and department stores including Major Cineplex Group (MAJOR), Siam Wellness Group (SPA), Central Pattana (CPN), Central Plaza Hotel (CENTEL) and Minor International (MINT).
According to analysts, MAJOR is the top beneficiary thanks to its relatively low price with a price upside of 14%.
The company can also expect a revenue stream from many international films set to be released in the remainder of the year.
Another top pick from the group is MK Restaurant Group (MK) with a price upside of 21% from the pre-Covid period. Analysts expect MK's operations will recover quickly after the easing of the lockdown.
The broker selected CPN as a top pick for department store stocks thanks to its high potential for a fast recovery.
CGS picked Berli Jucket (BJC), Central Retail Corporation (CRC) and CP ALL for retail stocks and Bangkok Bank, Kasikorn Bank and Siam Commercial Bank for banking stocks.
Globlex said the factors to monitor this week include severe flooding in many provinces and how they will impact the country's economic recovery, the Bank of Thailand's economic figures report and European September economic consumer confidence reports.
Ms Wilasinee said Asian and Thai stock markets are receiving positive sentiment from the success of Sichuan Clover, a Chinese pharmaceutical firm, in developing a vaccine against the Delta strain of Covid-19.
The firm's vaccines are said to be 79% effective in preventing severe and symptomatic infections caused by the Delta strain.